Moderna (MRNA) Change in Account Payables (2018 - 2026)

Moderna (MRNA) has reported Change in Account Payables for 9 consecutive years, with -$8.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Account Payables rose 82.98% year-over-year to -$8.0 million in Q2 2026; TTM through Jun 2026 was -$17.0 million, a 76.71% increase from a year earlier, with the FY2025 full-year figure at -$92.0 million, down 33.33% from the prior year.
• Change in Account Payables was -$8.0 million for Q2 2026 at Moderna, up from -$120.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $179.0 million in Q3 2023 and troughed at -$303.0 million in Q1 2024.
• A 5-year average of -$2.0 million and a median of $6.5 million in 2023 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables surged 905.56% in 2022 and plunged 234.29% in 2023, its largest moves.
• Over 5 years, Change in Account Payables stood at $151.0 million in 2022, then tumbled by 86.09% to $21.0 million in 2023, then surged by 61.9% to $34.0 million in 2024, then tumbled by 35.29% to $22.0 million in 2025, then sank by 136.36% to -$8.0 million in 2026.
• The last three Change in Account Payables figures came in at -$8.0 million (Q2 2026), -$120.0 million (Q1 2026), and $22.0 million (Q4 2025), per Business Quant data.